ArticleMedical journal of the Islamic Republic of Iran2026
Investigating the Correlation between Fecal Calprotectin and Gastrointestinal Involvement in Systemic Sclerosis Patients.
Article in Medical journal of the Islamic Republic of Iran, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic sclerosis (SSc) is a systemic autoimmune disease that is associated with gastrointestinal involvement. Calprotectin, as a heterodimer protein (S100A8/S100A9), is a good marker for active inflammatory bowel disease; this marker is a non-invasive and reproducible test. It is believed that fecal calprotectin (FC) increases in several inflammatory diseases, including rheumatoid arthritis, systemic lupus erythematosus, and SSc. In this study, we tried to measure the correlation between gastrointestinal involvement and FC level in SSc patients. Methods: This study is cross-sectional; 31 SSC patients were evaluated using the UCLA.SCTC 2.0, and then they were referred to the laboratory to assess their blood malnutrition biomarkers and stool sample to check FC. The quantitative data were analyzed using the T-test and the qualitative data using Chi-Square test. Results: The mean (SD) was 50.8 (4.2) for age and 15.0 (8.3) for ESR. Assessing the malnutrition markers showed that all assessed factors were in the normal range; the range of FC was higher than that of normal people (10-60). There was no correlation between FC and malnutrition markers, but a significant relationship between FC level and gastrointestinal symptoms such as diarrhea (74%), Constipation (74%), and bloating and abdominal distension (87 %) was detected. Conclusion: due to the high prevalence of gastrointestinal involvement in SSc patients, diagnosing gastrointestinal symptoms is an important step in ensuring patients' health. This study suggests that higher fecal calprotectin is an alarm for gastrointestinal involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.